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Background. The risks of occupational asthma (OA) from antibiotics are uncertain. We report 4 new cases and a systematic review
of the literature. Methods. Cases were identiﬁed through a specialist clinic, each underwent speciﬁc provocation testing (SPT). We
subsequently reviewed the published literature. Results. The patients were employed in the manufacture of antibiotics; penicillins
were implicated in three cases, in the fourth erythromycin, not previously reported to cause OA. In two, there was evidence of
speciﬁc IgE sensitisation. At SPT each developed a late asthmatic reaction and increased bronchial hyperresponsiveness. 36 case
reports have been previously published, 26 (citing penicillins or cephalosporins). Seven cross-sectional workplace-based surveys
found prevalences of 5–8%. Conclusions. OA in antibiotic manufacturers may be more common than is generally recognised.
Its pathogenesis remains unclear; immunological tests are of uncertain value and potential cases require conﬁrmation with SPT.
Further study of its frequency, mechanisms, and diagnosis is required.
1.Introduction
Among the several hundred workplace agents implicated as
causes of occupational asthma (OA), several are encountered
in the pharmaceutical manufacturing industry [1]. These
include antibiotics which, through inhalation, may induce
asthma in exposed employees. The role of dermal exposure
and the detailed pathogenesis of the condition—as with
many other low molecular mass causes of OA—remain
unclear.Immunologicaltestsareofuncertainvalueandmost
diagnoses require conﬁrmation with speciﬁc provocation
testing.
The ﬁrst case of occupational antibiotic allergy was
describedin1953,butarelativelysmallnumberofindividual
case reports have been published subsequently. Very large
quantities of antibiotics are produced in almost every
country but the frequency of OA in those who manufacture
them remains unclear. While prevalence estimates of around
10% have been reported [2–4], clinical experience suggests
a far less common problem. Here we report three new cases
of occupationally-induced penicillin allergy and, for the ﬁrst
time, a case of asthma induced by work in erythromycin
manufacture. The reports are supplemented by a systematic
literature review of antibiotic occupational asthma.
2. Methods
2.1. Case Reports. New cases were seen and diagnosed at
Royal Brompton Hospital in London, UK between 1995 and
2009. Speciﬁc IgE measurements, where attempted, were
carried out by either the radioallergosorbent test (RAST)
method or the commercial ImmunoCAP assay. Each patient
underwent controlled, single-blind, speciﬁc provocation
testing using a dust-tipping method, with small quantities of
the relevant antibiotic powder mixed with a larger amount
of dried lactose; active and control exposures were carried
out on sequential days with the patients having stopped
any asthma medications prior to the tests. Responses were
assessedusingserialFEV1measurementsfollowingchallenge
and by changes in bronchial responsiveness to inhaled
histamine using the Yan technique [5].2 Journal of Allergy
2.2. Systematic Review of Literature. We were not able to
identify any previous systematic review of this subject. We
searched the published literature using the Medline database
between 1953 and February 2010. Both key word- and text
word-based searches were performed with combinations
of the terms “occupational asthma”, “asthma”, “respiratory
sensitisation”,and“antibiotics”.Inaddition,weexaminedthe
reference lists of relevant articles. Both case reports (n =
21 papers) and workforce studies (n = 7) were retrieved
(one case report in Russian was not included.) and their
information extracted on to a standard form independently
by two reviewers.
We used a quantitative structure-activity relationship
(qSAR) model to examine the potential for each published
antibiotic to act as a respiratory sensitising agent. “Hazard
indices” for each were calculated, where possible, using the
Chemical Asthma Hazard Assessment Program [6]w h i c h
generates a risk prediction for organic compounds with a
molecular mass of less than 1kDa.
3.Findings
3.1. Case Reports (Table 1, Figure 1). Each of the four cases
was involved in the primary manufacture or formulation
of antibiotics in the United Kingdom and had presented
with new onset, work-related asthmatic symptoms. Three
worked with penicillins and their derivatives, the fourth with
a variety of medicines including erythromycin. This last, a
woman of 52, developed asthma 22 years previously, two
years after starting work on the packaging lines. She reported
that her symptoms worsened with exposure to granulated
erythromycin and on two occasions in the year prior to
referral had required treatment with oral corticosteroids. At
referral, she had normal spirometry, was demonstrated to be
atopic on skin prick testing, and completed a series of peak
ﬂow measurements which showed signiﬁcant variability on
both work and rest days, with no clear work-related pattern.
All four patients underwent single-blind, controlled
speciﬁc provocation testing using a dust-tipping method.
Each of the four developed a (predominantly) late asthmatic
reaction (Figure 1) accompanied by increased bronchial
hyperresponsiveness as demonstrated by a fall in histamine
PC20 concentration following challenge; these ﬁndings were
repeatable on further testing but not seen after identical
exposure to lactose powder alone. Following diagnosis, each
patient avoided further exposure at work to the causative
antibiotic with improvement or resolution of their symp-
toms. They were advised to avoid therapeutic use of the
relevant antibiotic.
3.2. Literature Review (Table 2). Previous published case
reports, including a total of 37 patients, are summarised
in Table 2. All but one of the cases was employed in the
manufacture of antibiotics. In 25 individuals, the diagnosis
was supported by speciﬁc inhalation testing which prompted
early, late, and dual asthmatic responses in 14 (56%), six
(24%), and three (12%) patients, respectively, with the
results of the remaining two positive tests being unspeciﬁed.
A hazard index was calculated for all bar two of the
implicated antibiotics (the exceptions being vancomycin and
colomycin,bothofwhichhaveamolecularmassgreaterthan
1kDa) and was in all cases between 0.99 and 1.00.
Three reports describe patients sensitised to penicillins.
In the ﬁrst, published in 1953, Eaton Roberts described
two employees in a US factory with clinical evidence of
OA ascribed to penicillin; apart from skin prick testing
with procaine penicillin (negative), he did not perform any
objective investigations [7]. Similarly, Tara in 1957 [8]a n d
Gaultier et al. in 1960 [9]r e p o r t e dat o t a lo fs i xF r e n c h
workers with clinical evidence of new-onset asthma after
exposure to penicillin dust.
Synthetic penicillins have also been reported as a cause
of work-related asthma. Davies et al. [10]u s e ds p e c i ﬁ c
provocation testing to conﬁrm OA from inhaled ampicillin
in three UK employees; in each case skin prick tests
with ampicillin and a variety of penicillin antigens were
negative. Oral challenge with ampicillin induced asthmatic
andotherallergicsymptomsintwoofthethreecases.Losada
et al. described two cases of dyspnoea after inhalation of
semisynthetic penicillins in workers in the manufacture of
antibiotics [11]; in neither case was there objective evidence
of immune sensitisation to these antibiotics. In Germany,
Wuthrich and Hartmann [12] described a single case of OA
from ampicillin; speciﬁc IgE antibodies to benzylpenicilloyl
were detected and cumulative inhalation testing with lac-
tose, tetracycline, ampicillin, and chloramphenicol caused
a delayed asthmatic reaction. A factory worker in Belgium
developed OA from amoxicillin [13] and subsequently, while
employed as a nurse, to latex. Piperacillin, a semisynthetic
penicillin, has also been reported to cause OA, the diagnosis
supported by both skin prick testing and an immediate
asthmatic response to speciﬁc inhalational testing [26].
There are several reports of cephalosporins and asso-
ciated precursors and derivatives as causative agents for
OA; 11 cases are summarised in Table 2 with supporting
evidence from speciﬁc provocation testing in ten, albeit most
frequently reported as immediate asthmatic responses only.
Serum and skin prick tests of immunological sensitisation
were only occasionally positive [15, 19, 20], and oral
challenges, both positive, were reported in just two patients
[11, 18].
The remaining eight reported cases developed OA
during the manufacture of antibiotics other than penicillins
or cephalosporins. Most have been in workers exposed to
the macrolide spiramycin, an antibiotic widely used in the
livestock industry and particularly with poultry so that
traces may be found in some chicken eggs. Davies and
Pepys [23] described the case of a pharmaceutical worker in
whom the diagnosis of OA from spiramycin was conﬁrmed
by speciﬁc inhalation challenge; he reported symptoms on
eating eggs but had negative skin prick tests to egg extracts.
Six other cases, in Canadian and Italian manufacturers
[4, 25], have been reported, in each case following speciﬁc
inhalation testing. In one case [25], an immediate asthmatic
response to provocation testing was also elicited by adipic
acid, an additive used to bind spiramycin. In the only case
of reported antibiotic OA outside the manufacturing sector,Journal of Allergy 3
Table 1: Cases of occupational asthma from antibiotics identiﬁed at Royal Brompton Hospital in the period 1995–2009.
case Year of
diagnosis
Workplace
exposure
Allergic
symptoms Latency Speciﬁc IgE Bronchial provocation test
Agent FEV1 response
Increase in
histamine
reactivity
a 1995 penicillin wheeze 19 years not done penicillin late Yes
b 1996 amoxicillin wheeze, cough 27 years penicilloyl G (+)
penicilloyl V (+) amoxicillin late yes
c 2000 amoxicillin wheeze, cough 27 years amoxicilloyl (+) amoxicillin late yes
d 2009 erythromycin wheeze,
rhinitis 2 years
erythromycin
ethylsuccinate
(−)
erythromycin
ethylsuccinate late Yes
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Figure 1: Changes in FEV1 and histamine reactivity following bronchial provocation testing in four antibiotic manufacturing workers.
Serial FEV1 measurements (y-axis) are plotted against time after provocation (x-axis); a fall of greater than 15% from baseline indicated a
signiﬁcant response. A late reaction (greater than two hours after challenge) is seen in all cases; an early reaction was also seen in case c. The
numerical value associated with each challenge plot is the postchallenge histamine PC20 result (mg/ml histamine): the lower the PC20 the
greater the degree of bronchial hyperresponsiveness.4 Journal of Allergy
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Paggiaro et al. [24] described dermatitis and asthma due to
spiramycin in a chick breeder; a skin prick test to spiramycin
was positive as was speciﬁc inhalation testing with chick feed
containing the antibiotic.
Menon and Das [22] documented in an Indian worker
immediate asthmatic reactions to intradermal, inhalation
and oral testing with tetracycline but no response to
inhalation testing with two antibiotics (nystatin and chloro-
mycetin) to which he was not exposed at work. Three cases
of OA from thiamphenicol—a methyl-sulfonyl analogue
of chloramphenicol—were reported by Ye et al. [27].
Vancomycin has been described as a cause of OA in a single
patient [28], the diagnosis conﬁrmed by serial peak ﬂow
measurements. The most recently reported case was of OA
due to the polymyxin antibiotic colomycin in an antibiotic
transport and storage worker, who demonstrated an early
asthmatic reaction following speciﬁc inhalation challenge
[29]; no evidence of speciﬁc IgE was found despite extensive
in vitro immunological testing.
3.3. Workforce Studies. We identiﬁed seven reports of epi-
demiological studies carried out in antibiotic manufacturing
sites; all but one was of cross-sectional design. In several
cases, the absence of detailed information on the size of
the exposed populations precludes any estimate of disease
prevalence.
Briatico-Vangosta et al. [2] surveyed 91 Italian work-
ers exposed to cephalosporins with a combination of a
symptoms questionnaire, skin prick and intradermal testing,
and “on-oﬀ” testing of asthma symptoms and pulmonary
function. On this basis, OA was reported for seven (8%)
employees. Skin testing produced immediate-type responses
in ﬁve workers with OA (in three cases with prick testing)
suggesting to the authors that the asthma had, in some cases
at least, arisen through a speciﬁc IgE-related mechanism.
Chida and Uehata [30] surveyed by interview 24 em-
ployees of a pharmaceutical factory which produced two
antibiotics (ampicillin and cephalexin) as well as an anti-
spasmodic and three anti-inﬂammatory drugs. Those with
respiratory symptoms (n = 18) underwent skin prick,
serum, and pulmonary function testing. Probable antibiotic-
relatedasthmawasclaimedforfouremployees,twoofwhom
had immediate responses to skin testing with ampicillin. In
the absence of any clear information on the population at
risk, a prevalence estimate is not available.
Phenylglycine acid chloride (PG-AC) is a highly reactive
compound used chieﬂy in the manufacture of ampicillin and
other antibiotic side chains. A survey of 24 workers involved
in the production of PG-AC [3] included a symptoms
questionnaire, examination of occupational health records,
skin testing, and spirometry. Seven workers were felt, on
the basis of their history alone, to have a respiratory
allergy to PG-AC; all had positive responses to prick and/or
intradermal skin testing with the conjugated compound.
Two were admitted to hospital for speciﬁc inhalation testing
with positive ﬁndings. A further seven employees were
deemed to have “irritant” respiratory responses to PG-AC
(allskintestsnegative)andinninethehistorywasconsidered
“equivocal”; two of this last group had positive skin test
results. The authors commented that the amino groups
in PG-AC predispose to the formation of hapten-protein
conjugates and hence its allergenicity. Again, in the absence
of any information on the size of the exposed workforce, an
estimate of prevalence in this setting is unavailable.
Carnevale et al. [31] studied 67 workers employed in
manufacturingandencapsulatingantibioticsinItaly.Follow-
ing questionnaire, clinical and laboratory investigations, two
(3%) cases of OA due to ampicillin were recorded. In both
cases skin tests were negative. Post- and preshift urine testing
conﬁrmed the systemic absorption of ampicillin by these
workers. A similar survey was reported by Carlesi et al. [32].
Among 26 employees in an antibiotic manufacturing plant,
eight (31%) claimed respiratory symptoms which in two
cases (8%) were suggestive of asthma. A further three em-
ployees had positive skin prick tests to penicillin G and/or
amoxicillin.
Two surveys of workers involved in spiramycin manufac-
ture have been reported. Malo and Cartier [4]i n v e s t i g a t e d
all 51 employees at a processing plant in Canada. Twelve,
on the basis of a compatible history or evidence of (work-
related) bronchial hyperreactivity, underwent speciﬁc in-
halation testing with positive ﬁndings in four cases. The
measured prevalence of 8% was considered by the authors,
to be a minimum estimate. In Italy, a 12-year prospective
study of 305 workers in a spiramycin-manufacturing plant
[33] suggested work-related asthma in 15 (5%), all of whom
had positive epicutaneous or intradermal skin tests to spira-
mycin. Four had additional symptoms of rhinitis and one
of urticaria. In the full study population, 41 employees
(13%) had positive skin tests, 37 (90%) of them with allergic
symptoms of some kind.
4. Discussion
Our cases add three to the previously reported eight cases
of OA attributed to inhalation of synthetic penicillins during
their manufacture, and the ﬁrst case of disease arising from
workplace exposure to erythromycin. An additional seven
cases of penicillin OA were reported to a UK national
surveillance scheme between 1989 and 2009 (THOR per-
sonal communication).
An examination of published ﬁndings from surveillance
schemes in other parts of the world found speciﬁc reference
to antibiotics in none although the Propulse scheme in
Quebec collated seven cases of OA (2.4% of the total)
attributed to “medical drugs” [34]. Our systematic review
of the remaining literature revealed a total of 37 cases
published over a period of almost 50 years, although others
were identiﬁed during the course of seven epidemiological
studies, the most recent of which was published over 20
years ago. It was often diﬃcult, in reviewing the workplace
surveys, to obtain meaningful estimates of prevalence but
what information was available suggests that about 10% of
those surveyed had disease suggestive of OA. Thus since the
ﬁrst report in 1953 there appears to have been only sporadic
attention paid to whatmay be a signiﬁcant occupational risk.
The clinical features of the published cases are similar to
those found in other examples of allergic OA and are broadly8 Journal of Allergy
indicative of an immediate-type respiratory hypersensitivity.
A latent period of asymptomatic exposure was reported for
all, usually of fewer than 24 months although occasionally
far longer, and rhinitis was a frequent accompaniment to
asthma symptoms. In those cases where speciﬁc inhalation
testing was used in diagnosis and the ﬁndings reported
in full, a late or dual asthmatic response was reported in
43%. In most cases of isolated early asthmatic responses to
speciﬁc provocation, there was evidence of immunological
sensitisation on skin or serum testing. Each of the implicated
antibiotics had a very high hazard index derived from a
quantitative structure-activity relationship analysis [35]; in
the clinical context of a patient with characteristic symp-
toms, index values such as these have a high positive pre-
dictive value for OA [36]. Finally, Roberts [7] reported the
apparently successful, subcutaneous desensitisation of two
patients with OA from penicillin.
Nonetheless, as with many other low-molecular-weight
causesofthedisease,theimmunologicaldetailsofantibiotic-
related OA remain unclear. While an IgE-associated mecha-
nism is likely in many cases, the possibility of sensitisation
arising from an alternative mechanism, perhaps through
cross-linking of cell surface receptors, cannot be ruled out.
Even when, as is not always the case, their techniques are
described, the variety of skin test methods used in the
published reports makes their interpretation and diagnostic
signiﬁcance uncertain. In any case, the results were often
negative and where they were not there is no systematic
information on the ﬁndings among exposed but non-
asthmatic employees. Similar comments apply to the use of
tests for serum-speciﬁc IgE antibodies which were less often
performed and more often negative although some success
has been recorded for in-house assays using cephalosporin
conjugates [20, 21] or thiamphenicol [27]. Thus, and prob-
ably in contrast to their use in oral antibiotic allergy [37],
the value of available tests for evidence of immunological
sensitisation in this context remains unclear.
Penicillins and cephalosporins are common causes of
oral drug allergy which in most cases is attributed to an IgE-
associated immune response to one or more hapten-protein
conjugates. Penicillins are composed of betalactam and thi-
azolidine rings with one or more diﬀerentiating side chains;
the instability of the betalactam causes its carbonyl group to
form amide-bonds with the amino groups of lysine residues
fromnearbyproteins.“Minor”antigenicdeterminants,some
formed from side chain-protein conjugates, may also induce
IgE immune responses. 7 aminocephalosporanic acid, the
active nucleus of cephalosporins, is structurally similar to
the active nucleus of the penicillins, consisting of betalactam
and 6 dyhydrothiazolidine rings. Hapten-protein conjugates
of the cephalosporin betalactam are relatively unstable. IgE
antibodies thatreacttocephalosporins detectalargenumber
of speciﬁc antigens derived from protein conjugates formed
from the side chain(s), the side chain plus a portion of the
betalactam ring, or the complete cephalosporin. On the basis
of ELISA inhibition assays in two patients with OA from
cefteram, Suh et al. [19] suggested that speciﬁc IgE responses
to the cephalosporin may involve haptens, new antigenic
determinants,orbothandarelikelytovarybetweenpatients.
Seven of the identiﬁed case reports describe oral chal-
lenges to the causative antibiotic (in six cases a penicillin or
cephalosporin) in patients with OA. All but one produced
an allergic response. The three cases reported by Davies
et al. [10] had subtly diﬀerent responses to inhaled and
oral (negative in one patient) provocation tests suggesting
the possibility that individually they were responsive to
diﬀerent hapten-protein antigens. The patient described by
Jimenez et al. [14] had allergic responses to both inhaled
and oral amoxicillin, but not to oral penicillin V suggesting
to the authors that the responsible antigenic determinant
lay in the aminohydroxyphenyl side-chain of amoxicillin.
In contrast, Sastre et al. [18] reported the case of a patient
with OA attributed to cefadroxil, a cephalosporin that shares
a side chain with amoxicillin. Oral challenge with cefadroxil,
but not with amoxicillin, produced an asthmatic response
suggesting that her sensitisation was to the dihydrothiazine
cephalosporin ring rather than to its side chain. Losada et al.
[11] reported a further patient with asthmatic responses to
both inhaled and oral cephalosporin but not to penicillin G.
Oral allergy may also develop in patients with OA attributed
to other antibiotics [22]. While the evidence base is weak,
andwecannotexcludethepossibilityofbiasinthoseselected
for oral challenge or in publication, we suggest that there is
suﬃcient experience to advise that patients with OA from
an inhaled antibiotic encountered at work should avoid
taking the same—or closely related—drug by mouth unless
its safety has been established by a carefully supervised
provocation test.
We have been unable to ﬁnd valid information on the
n u m b e r so fe x p o s e de m p l o y e e si na n yp a r t so ft h ew o r l db u t
we expect these to number many thousands. Much man-
ufacture is carried out in conditions where exposures to
employees are very low but this is not always the case, and
we note the general movement of pharmaceutical manu-
facturing away from its traditional base in western Europe
and North America. We note also that most published
evidence relates to older types of antibiotic. This is likely to
reﬂect the number and exposures of those involved in their
manufacture rather than any intrinsic hazard; the hazard
indices for newer antibiotics such as ﬂucloxacillin (0.909),
clarithromycin (0.997), tobramycin (1.0), and azithromycin
(1.0) are no lower. While cases of OA arising from antibiotic
manufacture are rarely published, the available epidemio-
logical evidence, admittedly scanty, sometimes deﬁcient and
all of it dated, suggests that the risks may be higher than
many appreciate. We suggest that further workplace-based
surveys, of careful design and supported by improvements
in immunological diagnosis, are required.
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